Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00498368 · ClinicalTrials.gov registry record · Phase 4
Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
NCT00498368: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT00498368 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 34 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00498368, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
Study Summary
This study was about IgA nephropathy, a form of kidney disease characterized by the presence of blood and protein in the urine. This study was done to determine if the medication rituximab could reduce protein in the patient's urine. Hypothesis: In patients with progressive IgA nephropathy an intravenous infusion of 1000 mg of rituximab on Day 1 and Day 15 and Days 168 and 182 is superior to conventional therapy in reducing 24 hour proteinuria, and slowing progression of chronic kidney disease.
Interventions
- DRUG Intravenous Rituximab
- DRUG ACE/ARB
- DIETARY_SUPPLEMENT Omega-3 Fatty Acid Fish Oil Supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-02 |
| Est. Completion | 2015-09 |
| Phase | Phase 4 |
What the finished NCT00498368 record still lists
NCT00498368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 3 interventions - of which Intravenous Rituximab is the first listed.
NCT00498368 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00498368 about?
NCT00498368 is a clinical study titled "Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy". This study was about IgA nephropathy, a form of kidney disease characterized by the presence of blood and protein in the urine. This study was done to determine if the medication rituximab could reduce protein in the patient's urine. Hypothesis: In patients with progressive IgA nephropathy an intra...
What is the current status of trial NCT00498368?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2009-02. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00498368?
The interventions under investigation include: Intravenous Rituximab (DRUG), ACE/ARB (DRUG), Omega-3 Fatty Acid Fish Oil Supplement (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00498368?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00498368's enrollment target sits among peer trials
34 1520th of 2000 higher than 473 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia